Biotechnology

Fate Therap

Google

GOOG

GOOGL

OpenAI

DXYZ

DPSK

TSLA

DOCS

GGLS

GGLL

TSDD

TSLL

TSLQ

09366

07766

07366

TSLR

FATE

GEMI

<p>OpenAI has been incredibly busy lately, dabbling in e-commerce, social media, and now launching a browser. Emmmm... it seems they've made enemies with half of the 'Seven Sisters.' Dolphin Research can hardly keep up with the trending topics every three days. Before the earnings report of <span class="security-tag" type="security-tag" counter_id="ST/US/GOOGL" name="Alphabet" trend="">$Alphabet(GOOGL.US)</span>, let's catch up on OpenAI's release of Atlas last week, an AI browser that claims to kick Chrome's butt. In fact, OpenAI's plan to launch an AI browser was leaked by Reuters back in July: OpenAI plans to launch an AI browser in the future...</p>

Alphabet - C

Alphabet

Destiny Tech100

DeepSeek

Tesla

Doximity

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

GraniteShares 2x Short TSLA Daily ETF

Direxion Daily TSLA Bull 2X Shares

AXS TSLA Bear Daily ETF

XI2CSOPTSLA-U

XL2CSOPTSLA

XI2CSOPTSLA

GraniteShares 2x Long TSLA Daily ETF

Park Hotels & Resort

Gemini Space Station

Google: My Fate is Determined by Myself, Not by OpenAI

Fate Therap released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 1.741 M (forecast USD 1.681 M), actual EPS USD -0.271 (forecast USD -0.284)

Fate Therap released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 5.277 M, actual EPS USD -0.8762

Tenthoff covers biotech stocks including Fate Therapeutics

Fate Therap released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 1.907 M (forecast USD 1.14 M), actual EPS USD -0.2874 (forecast USD -0.3463)

Fate Therap released FY2025 Semi-Annual Earnings on August 12 (EST), actual revenue USD 3.536 M, actual EPS USD -0.6052

Fate Therapeutics Analysts Lower Target Price

Wall Street 禅下调 Fate Therapeutics 评级为卖出

Fate Therapeutics Receives Analyst Hold Rating

Fate Therapeutics Announces Initial Success of FT819 Project in Treating SLE

Fate Therapeutics to Present Clinical Data on CAR T Candidate FT819 at EULAR 2025

BAIRD cuts FATE THERAPEUTICS target price

Fate Therap released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 1.629 M (forecast USD 1.184 M), actual EPS USD -0.3178 (forecast USD -0.3855)

Fate Therapeutics Reports Q1 2025 Revenue and FT819 Development Progress

Fate Therapeutics Inc reports Q1 loss of 38 cents per share

Fate Therapeutics Downgraded by Analysts and Target Price Reduced

Fate Therapeutics to Present iPSC Development Data at ASGCT Annual Meeting

XTX Topco Ltd Increases Stake in Fate Therapeutics in Q4

Fate Therapeutics Receives FDA Certification for FT819

Fate Therapeutics Grants Restricted Stock Units

Fate Therap released FY2024 Q4 earnings on March 5 (EST), actual revenue $1.86M (forecast $1.569M), actual EPS -$0.4427 (forecast -$0.425)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

Argenx

阿里拉姆制藥

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio